Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

NEWS FEEDS

The State of Comparative Effectiveness Research and the Environment for Health Care Decision Making (2012)

In its second annual survey of key health care stakeholders, NPC, working with the public health research firm Social & Scientific Systems (SSS), examined the environment for health care decisions, especially the current state of CER and its impact on medical decision making.

The purpose was to set a baseline for where key stakeholders believe we are today on CER and for tracking progress and judging future effects. According to the findings, there is clear recognition among key health care influentials about the importance of CER and its promise for the future. These stakeholders also expressed tempered optimism about progress in efforts to provide or improve the tools necessary for this research, and that any significant effects of CER are yet to be realized, and much work remains to be done.

CER Survey Highlights:

In its second survey to gauge attitudes around comparative effectiveness research (CER), the National Pharmaceutical Council was able to capture shifts in the conversation. 

CER continues to be a key issue of importance to stakeholders, but perceived importance has leveled off between 2011 and 2012.

  • More than half (53 percent) of survey respondents were “very familiar” with comparative effectiveness research and one-third of respondents were “somewhat familiar” with CER.
  • Of survey respondents, 95 percent said that CER was “somewhat” or “very important” to them or their organizations, a small increase from the 91 percent cited a year earlier.
  • However, the percentage that said CER was very important was lower than in the previous survey, declining from 71 percent to 64 percent. 

The Patient Centered Outcomes Research Institute (PCORI) continues to be recognized as an important player in CER.

  • Audiences who were “somewhat” to “very” familiar with PCORI rose by 8 percent over last year, increasing from 70 percent to 78 percent.
  • Between the 2011 survey and the 2012, PCORI showed the biggest jumps in recognition in key areas, compared to other organizations including the Agency for Healthcare Research and Quality (AHRQ), National Institutes of Health (NIH), Food and Drug Administration (FDA), private payers, academia and pharmaceutical industry. 
  • Stakeholders’ expectations of PCORI’s influence jumped most dramatically in two areas:
    • Establishing research standards – from 50 percent to 72 percent
    • Funding and monitoring research – from 44 percent to 60 percent

However, in key areas of importance, PCORI has yet to assume a leadership position among stakeholders. Survey respondents ranked who they thought would be the most important influencers in the next five years within these areas:

Who will help establish research standards around CER?

  1. AHRQ (83 percent)
  2. PCORI (72 percent)
  3. NIH (60 percent)

Who will establish research priorities?

  1. AHRQ (77 percent)
  2. NIH (71 percent)
  3. PCORI (67 percent)

Who will fund and monitor research?

  1. NIH (85 percent)
  2. AHRQ (74 percent)
  3. Pharmaceutical Medical Products Industry (66 percent)

(PCORI was rated 60 percent)

Who will conduct comparative effectiveness research?

  1. Academia (88 percent)
  2. Pharmaceutical Medical Products Industry (70 percent)
  3. NIH (50 percent)

Expectations are still strong that CER will improve health care decision-making, but few expect that impact to be felt soon.

  • In the next year, only 30 percent of respondents felt CER would moderately or substantially improve health care decision-making
  • In the next three years, 77 percent expected improvement
  • In the next five years, 91 percent expected improvement

CER Survey Parameters:

The survey, conducted from October 2011-February 2012, targeted key stakeholders who have an impact on, or are affected by, research involving medical effectiveness, including researchers/thought leaders; government; insurers and health plans; employers; business coalitions/HR specialists; and associations/trade groups. A total of 117 stakeholders participated.

Survey materials:

Newsletter Volume

E.V.I.dently: April 2016

MessageValue Assessment Through a Broader, Patient-Focused LensNPC has developed “Guiding Practices for Patient-Centered Value Assessment” to help...
Commentary and Testimony Page

NPC Comments on Revised PCORI Methodology Standards

March 28, 2016Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036 Dr. Robin...
YouTube Videos

2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

This one-hour webinar highlights the results of NPC's annual survey of comparative effectiveness research (CER) stakeholders and includes a panel...
Press Release

NPC Stakeholder Survey: Impact of Comparative Effectiveness Research On Health Care Decision-Making Still Three to Five Years in the Future

(Washington, DC, March 14, 2016)—The National Pharmaceutical Council (NPC) today released the results of its annual survey of stakeholder views on...
Press Release

NPC Stakeholder Survey: Impact of Comparative Effectiveness Research On Health Care Decision-Making Still Three to Five Years in the Future

(Washington, DC, March 14, 2016)—The National Pharmaceutical Council (NPC) today released the results of its annual survey of stakeholder views on...
Press Release

NPC Comments on CMS’ Announcement to Allow Broader Access to Publicly Funded Databases

(Washington, DC, June 2, 2015)—The National Pharmaceutical Council (NPC) today commented on the Centers for Medicare and Medicaid Services’ (CMS)...
Press Release

State Medicaid Directors Share Views on Comparative Effectiveness Research And Its Impact on Policy in National Pharmaceutical Council Survey

(Washington, DC, April 16, 2015)—A new survey conducted on behalf of the National Pharmaceutical Council (NPC) shows that state Medicaid directors...
Press Release

NPC Highlights Stakeholder Views on Comparative Effectiveness Research and the Environment for Health Care Decision-Making

(Washington, DC, March 26, 2015)—A new survey of health care stakeholders reveals continued optimism that comparative effectiveness research (CER)...
Commentary and Testimony Page

NPC Comments on Revised PCORI Methodology Standards

March 28, 2016Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036 Dr. Robin...
Commentary and Testimony Page

NPC Comments on PCORI Proposal for Peer Review of Primary Research and Public Release of Research Findings

November 7, 2014Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036Dear Dr....
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
Commentary and Testimony Page

Keeping Our Eye on the CER Ball

Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington will focus on the federal budget....
YouTube Videos

2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

This one-hour webinar highlights the results of NPC's annual survey of comparative effectiveness research (CER) stakeholders and includes a panel...
YouTube Videos

Comparative Effectiveness Research and the Environment for Health Care Decision-Making

During a March 26, 2015 webinar, the National Pharmaceutical Council discussed the results of its annual stakeholder survey on comparative...
YouTube Videos

Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice

National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, discusses a peer-reviewed study suggesting that changes are needed...
YouTube Videos

CER and the Environment for Health Care Decision-Making

The National Pharmaceutical Council’s (NPC) fourth annual survey of health care stakeholders is continuing to shed light on the current environment...
Blog Post

New Study Puts Previous 5 Years of NPC Annual CER Survey Into Perspective

For the last five years, we’ve had our fingers on the pulse of what health care stakeholders are thinking about comparative effectiveness research...
Blog Post

Key Considerations for Cost Effectiveness Thresholds

While putting a price tag on the value of health care services and the life years gained is common in countries including the United Kingdom, Canada...
Blog Post

CER Tweets of the Week: JCER Editorial on Treatment Sequences in Oncology; JNCCN Discusses CER Database Analyses (December 14-18, 2015)

What were comparative effectiveness research (CER) stakeholders talking about on Twitter this week? Popular topics included the Journal of...
Blog Post

#TBT: CER Collaborative & Environmental Trends

As part of our Throwback Thursday blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous research...
cersurvey16

2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

NPC's sixth annual survey of stakeholder views on comparative effectiveness research (CER) and the...

Developing Evidence that is Fit for Purpose: A Framework for Payer and Research Dialogue

A study published in the September 2015 issue of The American Journal of Managed Care introduces a...
  •  
  • 1 of 12
  • >